Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials

Hannu Uusitalo,1 Evgeniy Egorov,2 Kai Kaarniranta,3 Yuri Astakhov,4 Auli Ropo5 On behalf of the Switch Study Tafluprost Study Groups 1Department of Ophthalmology, SILK, University of Tampere, Tampere University Hospital, Tampere, Finland; 2Department of Ophthalmology, The Russian National Research...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Uusitalo H, Egorov E, Kaarniranta K, Astakhov Y, Ropo A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	preservative-free tafluprost Taflotan® preserved latanoprost Xalatan® ocular surface disease ocular symptoms and signs IOP patient-rated outcome meta-analysis. Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/318b9db2728f4009bca78d6c06d9b94c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:318b9db2728f4009bca78d6c06d9b94c
record_format	dspace
spelling	oai:doaj.org-article:318b9db2728f4009bca78d6c06d9b94c2021-12-02T03:14:07ZBenefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials1177-5483https://doaj.org/article/318b9db2728f4009bca78d6c06d9b94c2016-03-01T00:00:00Zhttps://www.dovepress.com/benefits-of-switching-from-latanoprost-to-preservative-free-tafluprost-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Hannu Uusitalo,1 Evgeniy Egorov,2 Kai Kaarniranta,3 Yuri Astakhov,4 Auli Ropo5 On behalf of the Switch Study Tafluprost Study Groups 1Department of Ophthalmology, SILK, University of Tampere, Tampere University Hospital, Tampere, Finland; 2Department of Ophthalmology, The Russian National Research Medical University, Moscow, Russia; 3Department of Ophthalmology, University of Eastern Finland, Kuopio University Hospital, Kuopio, Finland, 4Department of Ophthalmology, First Pavlov State Medical University of St Petersburg, Saint Petersburg, Russia, 5Global Medical Affairs, Santen Oy, Tampere, Finland Introduction: Glaucoma patients frequently exhibit ocular surface side effects during treatment with prostaglandin eye drops. The present work investigated whether glaucoma patients suffering from signs and symptoms of ocular surface disease while using preserved latanoprost eye drops benefited from switching to preservative-free tafluprost eye drops. Patients and methods: The analysis was based on 339 glaucoma patients enrolled in two Phase IIIb trials. The patients were required to have two symptoms, or one sign and one symptom of ocular surface disease at baseline, and at least 6 months preceding treatment with latanoprost eye drops preserved with benzalkonium chloride. All eligible patients were switched from latanoprost to preservative-free tafluprost for a total of 12 weeks. Ocular symptoms and ocular signs were evaluated at baseline and at 2 weeks, 6 weeks, and 12 weeks after commencing treatment with tafluprost. Intraocular pressure (IOP), drop discomfort, and treatment preference were evaluated to investigate the clinical efficacy and patient-related outcomes. Results: After 12 weeks of treatment with preservative-free tafluprost, the incidences of irritation/burning/stinging, foreign body sensation, tearing, itching, and dry eye sensation had diminished to one-third of those reported for preserved latanoprost at baseline. The incidences of blepharitis and corneal/conjunctival fluorescein staining had in turn decreased to one-half of those reported for preserved latanoprost. Severity of conjunctival hyperemia was halved during treatment with preservative-free tafluprost, and there was significant improvement in tear break-up time and tear production. A further reduction in IOP (~1 mmHg) was seen with preservative-free tafluprost compared with preserved latanoprost. Drop discomfort was alleviated during preservative-free tafluprost treatment, and an outstanding majority of patients (72%) preferred preservative-free tafluprost over preserved latanoprost. Conclusion: This meta-analysis confirmed that IOP remained at the same level after replacing benzalkonium chloride-preserved latanoprost eye drops with preservative-free tafluprost eye drops. Preservative-free tafluprost significantly decreased the symptoms and signs of ocular surface disease and outrated latanoprost in drop comfort and treatment preference. Keywords: Taflotan®, preserved latanoprost, Xalatan®, ocular surface disease, ocular symptoms and signs, IOP, patient-related outcomeUusitalo HEgorov EKaarniranta KAstakhov YRopo ADove Medical Pressarticlepreservative-free tafluprostTaflotan®preserved latanoprostXalatan®ocular surface diseaseocular symptoms and signsIOPpatient-rated outcomemeta-analysis.OphthalmologyRE1-994ENClinical Ophthalmology, Vol 2016, Iss Issue 1, Pp 445-454 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	preservative-free tafluprost Taflotan® preserved latanoprost Xalatan® ocular surface disease ocular symptoms and signs IOP patient-rated outcome meta-analysis. Ophthalmology RE1-994
spellingShingle	preservative-free tafluprost Taflotan® preserved latanoprost Xalatan® ocular surface disease ocular symptoms and signs IOP patient-rated outcome meta-analysis. Ophthalmology RE1-994 Uusitalo H Egorov E Kaarniranta K Astakhov Y Ropo A Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials
description	Hannu Uusitalo,1 Evgeniy Egorov,2 Kai Kaarniranta,3 Yuri Astakhov,4 Auli Ropo5 On behalf of the Switch Study Tafluprost Study Groups 1Department of Ophthalmology, SILK, University of Tampere, Tampere University Hospital, Tampere, Finland; 2Department of Ophthalmology, The Russian National Research Medical University, Moscow, Russia; 3Department of Ophthalmology, University of Eastern Finland, Kuopio University Hospital, Kuopio, Finland, 4Department of Ophthalmology, First Pavlov State Medical University of St Petersburg, Saint Petersburg, Russia, 5Global Medical Affairs, Santen Oy, Tampere, Finland Introduction: Glaucoma patients frequently exhibit ocular surface side effects during treatment with prostaglandin eye drops. The present work investigated whether glaucoma patients suffering from signs and symptoms of ocular surface disease while using preserved latanoprost eye drops benefited from switching to preservative-free tafluprost eye drops. Patients and methods: The analysis was based on 339 glaucoma patients enrolled in two Phase IIIb trials. The patients were required to have two symptoms, or one sign and one symptom of ocular surface disease at baseline, and at least 6 months preceding treatment with latanoprost eye drops preserved with benzalkonium chloride. All eligible patients were switched from latanoprost to preservative-free tafluprost for a total of 12 weeks. Ocular symptoms and ocular signs were evaluated at baseline and at 2 weeks, 6 weeks, and 12 weeks after commencing treatment with tafluprost. Intraocular pressure (IOP), drop discomfort, and treatment preference were evaluated to investigate the clinical efficacy and patient-related outcomes. Results: After 12 weeks of treatment with preservative-free tafluprost, the incidences of irritation/burning/stinging, foreign body sensation, tearing, itching, and dry eye sensation had diminished to one-third of those reported for preserved latanoprost at baseline. The incidences of blepharitis and corneal/conjunctival fluorescein staining had in turn decreased to one-half of those reported for preserved latanoprost. Severity of conjunctival hyperemia was halved during treatment with preservative-free tafluprost, and there was significant improvement in tear break-up time and tear production. A further reduction in IOP (~1 mmHg) was seen with preservative-free tafluprost compared with preserved latanoprost. Drop discomfort was alleviated during preservative-free tafluprost treatment, and an outstanding majority of patients (72%) preferred preservative-free tafluprost over preserved latanoprost. Conclusion: This meta-analysis confirmed that IOP remained at the same level after replacing benzalkonium chloride-preserved latanoprost eye drops with preservative-free tafluprost eye drops. Preservative-free tafluprost significantly decreased the symptoms and signs of ocular surface disease and outrated latanoprost in drop comfort and treatment preference. Keywords: Taflotan®, preserved latanoprost, Xalatan®, ocular surface disease, ocular symptoms and signs, IOP, patient-related outcome
format	article
author	Uusitalo H Egorov E Kaarniranta K Astakhov Y Ropo A
author_facet	Uusitalo H Egorov E Kaarniranta K Astakhov Y Ropo A
author_sort	Uusitalo H
title	Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials
title_short	Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials
title_full	Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials
title_fullStr	Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials
title_full_unstemmed	Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials
title_sort	benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two phase iiib clinical trials
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/318b9db2728f4009bca78d6c06d9b94c
work_keys_str_mv	AT uusitaloh benefitsofswitchingfromlatanoprosttopreservativefreetafluprosteyedropsametaanalysisoftwophaseiiibclinicaltrials AT egorove benefitsofswitchingfromlatanoprosttopreservativefreetafluprosteyedropsametaanalysisoftwophaseiiibclinicaltrials AT kaarnirantak benefitsofswitchingfromlatanoprosttopreservativefreetafluprosteyedropsametaanalysisoftwophaseiiibclinicaltrials AT astakhovy benefitsofswitchingfromlatanoprosttopreservativefreetafluprosteyedropsametaanalysisoftwophaseiiibclinicaltrials AT ropoa benefitsofswitchingfromlatanoprosttopreservativefreetafluprosteyedropsametaanalysisoftwophaseiiibclinicaltrials
_version_	1718401844370210816

Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials

Ejemplares similares